Evidence map›Paper›PMID 39092652›Full record

ReviewCurrent gene therapy2025

miRNA-Targeted Vaccines: A Promising Approach for Viral Attenuation and Immunogenicity Enhancement.

Abhijit Debnath, Rupa Mazumder, Avijit Mazumder, Soumya Tripathi, Arpita Dua, Rajesh Kumar Singh, Saloni Mangal, Jahanvi Sanchitra, Pratibha Pandey, Biplab Pal and 3 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current gene therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Abhijit DebnathNoida Institute of Engineering and Technology (Pharmacy Institute), 19 Knowledge Park-II, Institutional Area, Greater Noida-201306, Uttar Pradesh, India.ORCID 0000-0003-1056-1197
Rupa MazumderNoida Institute of Engineering and Technology (Pharmacy Institute), 19 Knowledge Park-II, Institutional Area, Greater Noida-201306, Uttar Pradesh, India.ORCID 0000-0002-1888-548X
Avijit MazumderNoida Institute of Engineering and Technology (Pharmacy Institute), 19 Knowledge Park-II, Institutional Area, Greater Noida-201306, Uttar Pradesh, India.ORCID 0000-0002-3053-8106
Soumya TripathiNoida Institute of Engineering and Technology (Pharmacy Institute), 19 Knowledge Park-II, Institutional Area, Greater Noida-201306, Uttar Pradesh, India.
Arpita DuaNoida Institute of Engineering and Technology (Pharmacy Institute), 19 Knowledge Park-II, Institutional Area, Greater Noida-201306, Uttar Pradesh, India.
Rajesh Kumar SinghInstitute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Saloni MangalNoida Institute of Engineering and Technology (Pharmacy Institute), 19 Knowledge Park-II, Institutional Area, Greater Noida-201306, Uttar Pradesh, India.
Jahanvi SanchitraNoida Institute of Engineering and Technology (Pharmacy Institute), 19 Knowledge Park-II, Institutional Area, Greater Noida-201306, Uttar Pradesh, India.ORCID 0009-0001-2730-1466
Pratibha PandeyNoida Institute of Engineering and Technology (Pharmacy Institute), 19 Knowledge Park-II, Institutional Area, Greater Noida-201306, Uttar Pradesh, India.
Biplab PalSchool of Pharmaceutical Sciences, Lovely Professional University, Jalandhar, Punjab, India.
Hema ChaudharySchool of Medical and Allied Sciences, K R Mangalam University, Sohna Road, Gurugram, India.ORCID 0000-0002-0207-8325
Parul SharmaFaculty of Pharmaceutical Sciences Shoolini University, Solan, Himachal Pradesh, India.
Shikha SrivastavaBhaskaracharya College of Applied Sciences, University of Delhi, Delhi, India.ORCID 0000-0002-1970-8370

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs) have emerged as a significant tool in the realm of vaccinology, offering novel approaches to vaccine development. This study investigates the potential of miRNAs in the development of advanced vaccines, with an emphasis on how they regulate immune response and control viral replication. We go over the molecular features of miRNAs, such as their capacity to direct post-transcriptional regulation toward mRNAs, hence regulating the expression of genes in diverse tissues and cells. This property is harnessed to develop live attenuated vaccines that are tissue-specific, enhancing safety and immunogenicity. The review highlights recent advancements in using miRNA-targeted vaccines against viruses like influenza, poliovirus, and tick-borne encephalitis virus, demonstrating their attenuated replication in specific tissues while retaining immunogenicity. We also explored the function of miRNAs in the biology of cancer, highlighting their potential to develop cancer vaccines through targeting miRNAs that are overexpressed in tumor cells. The difficulties in developing miRNA vaccines are also covered in this work, including delivery, stability, off-target effects, and the requirement for individualized cancer treatment plans. We wrap off by discussing the potential of miRNA vaccines and highlighting how they will influence the development of vaccination techniques for cancer and infectious diseases in the future.

Indexed as

Cancer VaccinesImmunogenicity, VaccineMicroRNAsNeoplasmsViral VaccinesVirus DiseasesAnimalsHumansVaccine DevelopmentVaccines, AttenuatedVirus ReplicationCancer VaccinesMicroRNAsVaccines, AttenuatedViral Vaccinesimmune regulationimmune responsemiRNAmiRNA vaccinesrational vaccine design.vaccinology

Identifiers

PMID39092652

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.